Exact Mass: 470.161
Exact Mass Matches: 470.161
Found 500 metabolites which its exact mass value is equals to given mass value 470.161
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Plumieride
Plumieride is a glycoside. Plumieride has been reported in Plumeria rubra, Allamanda cathartica Plumieride. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=511-89-7 (retrieved 2024-11-15) (CAS RN: 511-89-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
7-hydroxymethotrexate
7-hydroxymethotrexate is a metabolite of methotrexate. Methotrexate, abbreviated MTX and formerly known as amethopterin, is an antimetabolite and antifolate drug. It is used in treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It acts by inhibiting the metabolism of folic acid. Methotrexate began to replace the more toxic antifolate aminopterin starting in the 1950s. The drug was developed by Yellapragada Subbarao. (Wikipedia) D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
4-[3-(3,5-dihydroxyphenyl)-5-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-2-yl]benzene-1,2-diol
3-Carboxylic acid-picumast
Docarpamine
Imiglitazar
Plumieride
[2-Oxo-3-(3-oxo-1-phenylbutyl)chromen-4-yl] 2-acetyloxybenzoate
Alvaradoin M
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 3-O-senecioyl-alpha-L-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10S stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
Alvaradoin L
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10S stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
2-(1,3-Benzodioxol-5-yl)-3,5,6,8-tetramethoxy-7-[(3-methyl-2-butenyl)oxy]-4H-1-benzopyran-4-one
didymocalyxin B
6-[2-hydroxy-3-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5,7-dimethoxychromen-2-one
((5S,10R,11R,13S)-11,13-bis(4-hydroxyphenyl)-10,11-dihydro-5H-10,5-(epoxymethano)-dibenzo[a,d][7]annulene-1,3,6,8-tetraol)|(-)heimiol A|albiraminol C
1,4,8-trihydroxynaphthalene 1-O-[alpha-L-arabinofuranosyl-(1->6)]-beta-D-glucopyranoside
3-{{6-O-[(2E)-3-(4-hydroxyphenyl)-1-oxoprop-2-en-1-yl]-beta-D-glucopyranosyl}oxy}-3-methylglutaric acid|tangshenoside V
7-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2H-1-benzopyran-2-one|umbelliferone 7-O-rutinoside
4-[(6-O-beta-arabinopyranosyl-beta-glucopyranoside)oxy]-5-methoxycoumarin
4beta-hydroxy-6-O-(p-hydroxybenzoyl)-tetrahydrolinaride|americanoside
5-O-feruloyl-3-O-(beta-D-glucopyranosyl)-2-deoxy-D-ribono-gamma-lactone|[(2R,3S)-3-[(beta-D-glucopyranosyl)oxy]-1,2,3,4-tetrahydro-5-oxofuran-2-yl]methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(2alpha,3alpha,4beta,5alpha,12R,19alpha)-6,7-didehydro-3,4-dihydroxy-17-methoxy-8-oxo-2,21-cycloaspidospermidine-1,3-dicarboxylic acid dimethyl ester|3-oxo-kopsingine|kopsidarine
5-[4-[2-(3-Hydroxyphenyl)ethyl]phenoxy]-6-methoxy-9,10-dihydrophenanthrene-1,2,7-triol
O-Rutinosylumbelliferone
7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-2-one is a natural product found in Morus nigra with data available.
5-[2-(6-Hydroxy-4,7-dimethoxy-benzofuran-5-yl)-2-oxo-ethyl]-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium
[2,6-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohex-3-en-1-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
6-[2-hydroxy-3-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5,7-dimethoxychromen-2-one
7-Hydroxymethotrexat
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists CONFIDENCE standard compound; INTERNAL_ID 2731 CONFIDENCE standard compound; INTERNAL_ID 8505
6-[2-hydroxy-3-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5,7-dimethoxychromen-2-one [IIN-based: Match]
6-[2-hydroxy-3-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5,7-dimethoxychromen-2-one_major
6-[2-hydroxy-3-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5,7-dimethoxychromen-2-one_68.0\\%
Ala Cys Asp Tyr
Ala Cys Phe Met
Ala Cys Met Phe
Ala Cys Tyr Asp
Ala Asp Cys Tyr
Ala Asp Glu His
Ala Asp His Glu
Ala Asp Tyr Cys
Ala Glu Asp His
Ala Glu His Asp
Ala Phe Cys Met
Ala Phe Met Cys
Ala His Asp Glu
Ala His Glu Asp
Ala Met Cys Phe
Ala Met Phe Cys
Ala Met Ser Tyr
Ala Met Tyr Ser
Ala Ser Met Tyr
Ala Ser Tyr Met
Ala Tyr Cys Asp
Ala Tyr Asp Cys
Ala Tyr Met Ser
Ala Tyr Ser Met
Cys Ala Asp Tyr
Cys Ala Phe Met
Cys Ala Met Phe
Cys Ala Tyr Asp
Cys Cys Phe Val
Cys Cys Val Phe
Cys Asp Ala Tyr
Cys Asp Phe Ser
Cys Asp His Pro
Cys Asp Pro His
Cys Asp Ser Phe
Cys Asp Tyr Ala
Cys Glu Gly Tyr
Cys Glu Tyr Gly
Cys Phe Ala Met
Cys Phe Cys Val
Cys Phe Asp Ser
Cys Phe Met Ala
Cys Phe Ser Asp
Cys Phe Thr Thr
Cys Phe Val Cys
Cys Gly Glu Tyr
Cys Gly Tyr Glu
Cys His Asp Pro
Cys His Pro Asp
Cys Met Ala Phe
Cys Met Phe Ala
Cys Pro Asp His
Cys Pro His Asp
Cys Ser Asp Phe
Cys Ser Phe Asp
Cys Ser Val Tyr
Cys Ser Tyr Val
Cys Thr Phe Thr
Cys Thr Thr Phe
Cys Val Cys Phe
Cys Val Phe Cys
Cys Val Ser Tyr
Cys Val Tyr Ser
Cys Tyr Ala Asp
Cys Tyr Asp Ala
Cys Tyr Glu Gly
Cys Tyr Gly Glu
Cys Tyr Ser Val
Cys Tyr Val Ser
Asp Ala Cys Tyr
Asp Ala Glu His
Asp Ala His Glu
Asp Ala Tyr Cys
Asp Cys Ala Tyr
Asp Cys Phe Ser
Asp Cys His Pro
Asp Cys Pro His
Asp Cys Ser Phe
Asp Cys Tyr Ala
Asp Glu Ala His
Asp Glu His Ala
Asp Phe Cys Ser
Asp Phe Ser Cys
Asp His Ala Glu
Asp His Cys Pro
Asp His Glu Ala
Asp His Pro Cys
Asp Pro Cys His
Asp Pro His Cys
Asp Ser Cys Phe
Asp Ser Phe Cys
Asp Ser Ser Tyr
Asp Ser Tyr Ser
Asp Tyr Ala Cys
Asp Tyr Cys Ala
Asp Tyr Ser Ser
Glu Ala Asp His
Glu Ala His Asp
Glu Cys Gly Tyr
Glu Cys Tyr Gly
Glu Asp Ala His
Glu Asp His Ala
Glu Glu Gly His
Glu Glu His Gly
Glu Gly Cys Tyr
Glu Gly Glu His
Glu Gly His Glu
Glu Gly Tyr Cys
Glu His Ala Asp
Glu His Asp Ala
Glu His Glu Gly
Glu His Gly Glu
Glu Tyr Cys Gly
Glu Tyr Gly Cys
Phe Ala Cys Met
Phe Ala Met Cys
Phe Cys Ala Met
Phe Cys Cys Val
Phe Cys Asp Ser
Phe Cys Met Ala
Phe Cys Ser Asp
Phe Cys Thr Thr
Phe Cys Val Cys
Phe Asp Cys Ser
Phe Asp Ser Cys
Phe Met Ala Cys
Phe Met Cys Ala
Phe Met Ser Ser
Phe Ser Cys Asp
Phe Ser Asp Cys
Phe Ser Met Ser
Phe Ser Ser Met
Phe Thr Cys Thr
Phe Thr Thr Cys
Phe Val Cys Cys
Gly Cys Glu Tyr
Gly Cys Tyr Glu
Gly Glu Cys Tyr
Gly Glu Glu His
Gly Glu His Glu
Gly Glu Tyr Cys
Gly His Glu Glu
Gly Met Thr Tyr
Gly Met Tyr Thr
Gly Thr Met Tyr
Gly Thr Tyr Met
Gly Tyr Cys Glu
Gly Tyr Glu Cys
Gly Tyr Met Thr
Gly Tyr Thr Met
His Ala Asp Glu
His Ala Glu Asp
His Cys Asp Pro
His Cys Pro Asp
His Asp Ala Glu
His Asp Cys Pro
His Asp Glu Ala
His Asp Pro Cys
His Glu Ala Asp
His Glu Asp Ala
His Glu Glu Gly
His Glu Gly Glu
His Gly Glu Glu
His Pro Cys Asp
His Pro Asp Cys
Met Ala Cys Phe
Met Ala Phe Cys
Met Ala Ser Tyr
Met Ala Tyr Ser
Met Cys Ala Phe
Met Cys Phe Ala
Met Phe Ala Cys
Met Phe Cys Ala
Met Phe Ser Ser
Met Gly Thr Tyr
Met Gly Tyr Thr
Met Ser Ala Tyr
Met Ser Phe Ser
Met Ser Ser Phe
Met Ser Tyr Ala
Met Thr Gly Tyr
Met Thr Tyr Gly
Met Tyr Ala Ser
Met Tyr Gly Thr
Met Tyr Ser Ala
Met Tyr Thr Gly
Pro Cys Asp His
Pro Cys His Asp
Pro Asp Cys His
Pro Asp His Cys
Pro His Cys Asp
Pro His Asp Cys
Ser Ala Met Tyr
Ser Ala Tyr Met
Ser Cys Asp Phe
Ser Cys Phe Asp
Ser Cys Val Tyr
Ser Cys Tyr Val
Ser Asp Cys Phe
Ser Asp Phe Cys
Ser Asp Ser Tyr
Ser Asp Tyr Ser
Ser Phe Cys Asp
Ser Phe Asp Cys
Ser Phe Met Ser
Ser Phe Ser Met
Ser Met Ala Tyr
Ser Met Phe Ser
Ser Met Ser Phe
Ser Met Tyr Ala
Ser Ser Asp Tyr
Ser Ser Phe Met
Ser Ser Met Phe
Ser Ser Tyr Asp
Ser Val Cys Tyr
Ser Val Tyr Cys
Ser Tyr Ala Met
Ser Tyr Cys Val
Ser Tyr Asp Ser
Ser Tyr Met Ala
Ser Tyr Ser Asp
Ser Tyr Val Cys
Thr Cys Phe Thr
Thr Cys Thr Phe
Thr Phe Cys Thr
Thr Phe Thr Cys
Thr Gly Met Tyr
Thr Gly Tyr Met
Thr Met Gly Tyr
Thr Met Tyr Gly
Thr Thr Cys Phe
Thr Thr Phe Cys
Thr Tyr Gly Met
Thr Tyr Met Gly
Val Cys Cys Phe
Val Cys Phe Cys
Val Cys Ser Tyr
Val Cys Tyr Ser
Val Phe Cys Cys
Val Ser Cys Tyr
Val Ser Tyr Cys
Val Tyr Cys Ser
Val Tyr Ser Cys
Tyr Ala Cys Asp
Tyr Ala Asp Cys
Tyr Ala Met Ser
Tyr Ala Ser Met
Tyr Cys Ala Asp
Tyr Cys Asp Ala
Tyr Cys Glu Gly
Tyr Cys Gly Glu
Tyr Cys Ser Val
Tyr Cys Val Ser
Tyr Asp Ala Cys
Tyr Asp Cys Ala
Tyr Asp Ser Ser
Tyr Glu Cys Gly
Tyr Glu Gly Cys
Tyr Gly Cys Glu
Tyr Gly Glu Cys
Tyr Gly Met Thr
Tyr Gly Thr Met
Tyr Met Ala Ser
Tyr Met Gly Thr
Tyr Met Ser Ala
Tyr Met Thr Gly
Tyr Ser Ala Met
Tyr Ser Cys Val
Tyr Ser Asp Ser
Tyr Ser Met Ala
Tyr Ser Ser Asp
Tyr Ser Val Cys
Tyr Thr Gly Met
Tyr Thr Met Gly
Tyr Val Cys Ser
Tyr Val Ser Cys
7-Hydroxymethotrexate
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
4-(5,7-Dimethoxy-2-oxo-2H-chromen-6-yl)-3-hydroxy-2-methyl-2-butanyl ?-D-glucopyranoside
1-[[2-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester
N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio]benzamide
Docarpamine
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Imiglitazar
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
7-[2-(1,3-Benzothiazol-2-ylthio)ethyl]-1,3-dimethyl-8-(3-methyl-1-piperidinyl)purine-2,6-dione
N-(2-furanylmethyl)-2-[[oxo-(3,4,5-trimethoxyphenyl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
O-(3-O-beta-D-galactosyl-N-acetyl-alpha-D-galactosaminyl)-L-serine
A serine derivative that is L-serine having a 3-O-beta-D-galactosyl-N-acetyl-alpha-D-galactosaminyl moiety attached to the side-chain oxygen.
N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine
(E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutyric acid
Alvaradoin K
A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10R stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.
5-Formimidoyltetrahydrofolate(2-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
7-{4-[4-(2-fluorophenyl)piperazin-1-yl]-4-oxobutyl}-6-thioxo-6,7-dihydro[1,3]dioxolo[4,5-g]quinazolin-8(5H)-one
5-[2-(6-Hydroxy-4,7-dimethoxy-1-benzofuran-5-yl)-2-oxoethyl]-4-methoxy-6,6-dimethyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium
3-[2-(tert-butylamino)-2-oxoethoxy]-N-(4-chloro-2,5-dimethoxyphenyl)-2-naphthalenecarboxamide
4-[3-(1,3-Diphenyl-4-pyrazolyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-4-oxobutanoic acid
4-(3,5-dimethyl-1-pyrazolyl)-N-[2-methoxy-5-(4-morpholinylsulfonyl)phenyl]benzamide
N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide
methyl 3-[3-[4-(3-chlorophenyl)piperazin-1-yl]propanoylamino]-4-methoxy-1H-indole-2-carboxylate
(2S)-3-(1H-indol-3-yl)-2-[[2-(4-methyl-6-oxobenzo[c]chromen-3-yl)oxyacetyl]amino]propanoic acid
N-[[(4S,5S)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine
A derivative of L-serine having a 3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl moiety attached to the side-chain oxygen.
(3E,5R)-5-[(1R,5R,6Z,9Z,13R,15R)-5-(acetyloxy)-10-chloro-6-methyl-3-oxo-2,14-dioxabicyclo[11.2.1]hexadeca-6,9-dien-15-yl]-5-hydroxy-3-methylpent-3-enoic acid
N-[[(4S,5S)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
(6R,7R,8S)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8S)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylphenyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[[(4R,5S)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5R)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5S)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4S,5R)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4R,5R)-8-(2-cyclopropylethynyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
N-[[(4S,5R)-8-(2-cyclopropylethynyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylmethanesulfonamide
(6S,7S,8S)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8S)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(4-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-4-(3-fluorophenyl)sulfonyl-8-(hydroxymethyl)-7-[4-(4-methylpent-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylphenyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylphenyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
D-Galactosyl-3-(N-acetyl-beta-D-galactosaminyl)-L-serine
(2S)-3-(2-acetamido-2-deoxy-3-O-beta-D-galactopyranosyl-alpha-D-galactopyranosyloxy)-2-azaniumylpropanoate
methyl 2-[(5E)-5-[(3,4-diethoxyphenyl)methylidene]-3-(4-methoxyphenyl)-4-oxo-2-sulfanylideneimidazolidin-1-yl]acetate
[(2->6)-alpha-D-glucosyl-(1->4)-N-acetyl-alpha-D-neuraminosyl]n
[2,6-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohex-3-en-1-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
5-Formimidoyltetrahydrofolate(2-)
Dianion of 5-formimidoyltetrahydrofolic acid arising from deprotonation of both carboxylic acid functions.
FR177391
A 14-membered macrolide isolated from the Serratia liquefaciens and exhibits anti-hyperlipidemic activity.
O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine zwitterion
Zwitterionic form of O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.
O-(3-O-beta-D-galactosyl-N-acetyl-alpha-D-galactosaminyl)-L-serine zwitterion
An amino acid zwitterion that is the zwitterionic form of O-(3-O-beta-D-galactosyl-N-acetyl-alpha-D-galactosaminyl)-L-serine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.
AZD1283
AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders[1][2].
SF-22
SF-22 is a potent and brain-penetrant antagonist of neuropeptide Y receptor (Y2R), with the IC50 value of 750 nM. SF-22 plays an important role in neurological disease[1].
3-(3,5-dihydroxyphenyl)-1-(4-hydroxybenzoyl)-2-(4-hydroxyphenyl)-2,3-dihydro-1h-indene-4,6-diol
methyl (1r,4as,7s,7as)-4'-[(1s)-1-hydroxyethyl]-5'-oxo-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4a,7a-dihydro-1h-spiro[cyclopenta[c]pyran-7,2'-furan]-4-carboxylate
17-(3,4-dihydroxyphenyl)-9-(4-hydroxyphenyl)-8-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-2,4,6,11,13,15-hexaene-5,13,15-triol
17-(3,5-dihydroxyphenyl)-9-(4-hydroxyphenyl)-8-oxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-2,4,6,11,13,15-hexaene-5,13,15-triol
6,9-dihydroxy-9-methyl-7-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-8,10-dihydro-7h-tetracene-5,12-dione
11,12-dimethyl (1s,12r,15s,20s)-19-formyl-22-oxo-6,8-dioxa-11,19-diazahexacyclo[13.5.3.0¹,¹².0²,¹⁰.0⁵,⁹.0¹⁵,²⁰]tricosa-2(10),3,5(9)-triene-11,12-dicarboxylate
(4s,6r,6as,9r,10s,10as)-6,10-bis(acetyloxy)-6a,9-dihydroxy-3-(methoxymethyl)-6,9-dimethyl-2-oxo-4h,5h,7h,8h,10h-naphtho[4a,4-b]furan-4-yl acetate
(5-oxo-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxolan-2-yl)methyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(2s,3r,4s,5s,6r)-2-[(4,8-dihydroxynaphthalen-1-yl)oxy]-6-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol
[(2r,3s)-5-oxo-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxolan-2-yl]methyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(1s,2s,3s,11r,12r,14r,17r,19s,20r,23r)-2,6,6,14,20-pentamethyl-7,16,18,21,24-pentaoxaspiro[heptacyclo[12.8.1.1³,¹⁹.0¹,¹⁹.0²,¹².0⁵,¹⁰.0¹⁷,²³]tetracosane-11,2'-oxirane]-4,9-diene-8,15,22-trione
4-[({10-benzyl-7,9,10,10a-tetrahydroxy-3-oxo-1h,2h,5h-pyrrolo[1,2-b]isoquinolin-5-yl}(hydroxy)methylidene)amino]butanoic acid
4-bromobenzyl-labda-7,12(e),14-triene-17-oate
{"Ingredient_id": "HBIN010275","Ingredient_name": "4-bromobenzyl-labda-7,12(e),14-triene-17-oate","Alias": "NA","Ingredient_formula": "C27H35BrO2","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2618","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}